<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100773">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01842659</url>
  </required_header>
  <id_info>
    <org_study_id>CRC 2011</org_study_id>
    <secondary_id>AOM 11003</secondary_id>
    <nct_id>NCT01842659</nct_id>
  </id_info>
  <brief_title>Prenatal Screening for Imprinting Anomalies Implicated in Beckwith Wiedemann and Silver Russell Syndromes</brief_title>
  <acronym>DASIRUWIBE</acronym>
  <official_title>Prenatal Screening for Imprinting Anomalies Implicated in Beckwith Wiedemann and Silver Russell Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: French Data Protection Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Losses of imprinting are involved in various syndromes. Those occurring in the 11p15 region
      lead to Beckwith-Wiedemann and Silver-Russell Syndromes. These losses of imprinting follow a
      mosaic pattern, rendering their detection difficult, especially given the scarcity of
      available DNA in amniotic fluid. Thus, in spite of growing demand, prenatal diagnosis (PND)
      for imprinting abnormalities of the 11p15 region is not available.

      The recent development of a quantitative PCR method that permits the methylation index (MI)
      of imprinted regions to be calculated renders PND technically possible. Nevertheless,
      because of the mosaic nature of these anomalies, it is essential to verify that the
      methylation pattern of the 11p15 region obtained from the amniotic fluid matches that
      obtained from the blood.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the agreement between the methylation index of the 11p15 region obtained using
      DNA extracted from amniocytes and that extracted from cord blood leukocytes, by calculating
      the intraclass correlation coefficient (ICC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Methylation Index (MI) of the 11p15 region using DNA extracted</measure>
    <time_frame>27 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the agreement between the MI of the 11p15 region obtained using DNA extracted from amniocytes and that extracted from cord blood leukocytes, by calculating the intraclass correlation coefficient (ICC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MI using the placenta</measure>
    <time_frame>27 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To calculate the MI using the placentas of the same individuals and to evaluate its agreement with the MIs obtained above.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Pregnant Women Requiring Amniocentesis</condition>
  <arm_group>
    <arm_group_label>Pregnant women requiring amniocentesis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant women requiring amniocentesis</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Methylation Index</intervention_name>
    <description>To calculate the methylation index (MI) of imprinted regions.</description>
    <arm_group_label>Pregnant women requiring amniocentesis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women, 18 years of age or older

          -  Requiring amniotic fluid sampling in the context of pregnancy care after 15 weeks of
             amenorrhea

          -  Having provided written informed consent

          -  Followed at Trousseau Hospital during their pregnancy

          -  Covered by or beneficiary of a state health insurance program (except for medical aid
             programs)

        Exclusion Criteria:

          -  Warning signs on ultrasound that require a medical termination of pregnancy to be
             discussed even before amniocentesis is performed
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Netchine, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene Netchine, PU-PH</last_name>
    <phone>+ 33 (0) 1 44 73 66 49</phone>
    <email>irene.netchine@trs.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Explorations fonctionnelles endocriniennes</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marie Jouannic, PU-PH</last_name>
      <phone>+33 (0)1 44 73 80 85</phone>
      <email>jean-marie.jouannic@trs.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Marie Jouannic, PU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 14, 2013</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MI</keyword>
  <keyword>amniocentesis</keyword>
  <keyword>cord blood</keyword>
  <keyword>placenta</keyword>
  <keyword>Silver Russell Syndrome</keyword>
  <keyword>Beckwith Wiedemann Syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Beckwith-Wiedemann Syndrome</mesh_term>
    <mesh_term>Silver-Russell Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
